Profit before deduction of interest, taxes, depreciation and amortization: immunoprecise.com (IPA)
EBITDA fluctuations for ImmunoPrecise Antibodies (IPA) demonstrate the impact of fierce competition regarding molecule development speed within the CRO sector. Growth is driven by the synthesis of IT and genetics for antibody discovery, as well as strict compliance with environmental standards for biomaterial disposal. The value of expresses the latest metric level, allowing for a real-time assessment of the company's actual operating cash flow excluding depreciation and amortization.
ImmunoPrecise Antibodies Ltd. (IPA) - metric breakdowns and financial figures
- market value and analyst target forecast:
- company stock exchange capitalization indicators:
- book capitalization indicators:
- debt level and financial liquidity data:
Total Debt to Equity Ratio ImmunoPrecise Antibodies|IPA - Long-Term Debt to Capital|Short-Term Debt to Capital Coefficient ImmunoPrecise Antibodies Ltd|IPA - Company Debts|Debts to Net Assets ImmunoPrecise Antibodies|IPA - Company Long-Term Debts|Short-Term Debt ImmunoPrecise Antibodies|Intermediate Coverage Ratio immunoprecise.com
- earnings and market ratios statistics:
IPA - Net Profit|Projected Future Earnings ImmunoPrecise Antibodies|IPA - Price to Earnings Ratio|Price to Future Earnings Ratio ImmunoPrecise Antibodies Ltd|IPA - Price/Earnings to Growth Multiple|Enterprise Value to Operating Income Before Depreciation Ratio ImmunoPrecise Antibodies|IPA - Operating profit EBITDA|Net earnings per share for the last four quarters ImmunoPrecise Antibodies|IPA - Net earnings per share (EPS TTM)|Year-over-year earnings per share growth for the last twelve months immunoprecise.com|IPA - Earnings per share growth in current year|Expected net earnings per share growth next year ImmunoPrecise Antibodies
Analysis of all company metrics:IPA ImmunoPrecise Antibodies
This indicator measures real cash flow from core operations, excluding all non-cash accounting accruals and GAAP distortions to reveal true operational efficiency. An analysis of the EBITDA timeline enables a stress test of the asset, confirming the ability of ImmunoPrecise Antibodies (IPA) to generate profit through the organic development of AI services and strategic partnerships without relying on capital-intensive mergers and acquisitions.
Who ImmunoPrecise Antibodies competes with
Tempus (TEM) - Profit before interest, taxes and amortization|QGEN - Profit before payment of interest, taxes and amortization|Profit before deduction of interest, taxes, depreciation and amortization IONS|Repligen (RGEN) - Profit before payment of interest, taxes and amortization|Avidity Biosciences Inc - Income before deduction of interest, taxes and amortization|CRSP (CRISPR Therapeutics Corp) - Operating profit EBITDA|Profit before interest, taxes and amortization GeneDx Corp WGS|Operating profit EBITDA RARE|Operating profit before deduction of amortization beamtx.com BEAM|Operating profit EBITDA SRPT (Sarepta)|Operating income before deduction of amortization Twist Bioscience Inc (TWST)|TXG - Profit before payment of interest, taxes and amortization|Operating income before deduction of amortization Intellia Corp NTLA|STOK: Operating profit EBITDA|Profit before interest, taxes and amortization biolifesolutions.com (BLFS)|Operating profit before deduction of amortization WVE|MAZE: Income before deduction of interest, taxes and amortization|Operating profit EBITDA SION|Operating profit EBITDA Prime Medicine Bio (PRME)|Profit before payment of interest, taxes and amortization Taysha Gene Therapies TSHA|QURE: Operating profit before amortization|MGTX: Operating profit before deduction of amortization|REGENXBIO Inc - Company profit before taxes, interest and amortization|SLDB: Operating profit EBITDA|OCGN - Operating income before deduction of amortization|PACB (Pacific Biosciences) - Operating profit EBITDA|Profit before payment of interest, taxes and amortization BNTC|Profit before payment of interest, taxes and amortization Design Therapeutics, Inc. (DSGN)|RCKT - Profit before interest, taxes and amortization|Operating profit EBITDA FDMT (4D Molecular Therapeutics Inc)|LXEO: Operating profit before amortization|Korro Bio, Inc - Operating profit EBITDA|Operating income before deduction of amortization editasmedicine.com EDIT|SLN: Operating profit EBITDA|Profit before interest, taxes and amortization ProQR Therapeutics (PRQR)|Profit before payment of interest, taxes and amortization Codexis Inc|Sangamo BioSciences (SGMO) - Operating income before deduction of amortization|Operating profit EBITDA NAUT|Operating income before deduction of amortization metagenomi.co|Profit before payment of interest, taxes and amortization Precision BioSciences, Inc. DTIL|GBIO (Generation Bio Co) - Profit before deduction of interest, taxes, depreciation and amortization|Boundless Bio, Inc - Operating profit EBITDA|XCUR - Operating profit EBITDA|IMNN: Operating profit EBITDA|Operating profit before amortization PHIO|Profit before payment of interest, taxes and amortization Mustang Bio Inc|Operating profit before amortization RNAZ (TransCode)|Operating profit EBITDA BNGO|Operating profit EBITDA Applied DNA Corp (APDN)|Operating profit EBITDA BLUE (bluebird bio, Inc.)|Operating income before deduction of amortization omegatherapeutics.com (OMGA)|OMIC - Profit before payment of interest, taxes and amortization|Regulus Therapeutics, Inc. (RGLS) - Operating profit before deduction of amortization|Syros (SYRS) - Profit before payment of interest, taxes and amortization|Operating profit before deduction of amortization Telesis Bio, Inc|Operating profit before deduction of amortization TCON|Operating profit EBITDA unitybiotechnology.com
